STOCK TITAN
  1. Home
  2. News
  3. KALV

KalVista Pharmaceuticals Inc - KALV STOCK NEWS

Welcome to our dedicated news page for KalVista Pharmaceuticals (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KalVista Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KalVista Pharmaceuticals's position in the market.

News
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) appoints William C. Fairey, former Chief Commercial Officer at MyoKardia, to its Board of Directors. Mr. Fairey brings over 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry. His expertise in rare diseases and product launches will support KalVista's focus on the FDA submission, potential approval, and commercial launch of sebetralstat, a treatment for hereditary angioedema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
management
-
News
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) will participate in the 23rd Annual Needham Virtual Healthcare Conference. The company focuses on protease inhibitors and offers a webcast of the presentation on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. granted nine newly-hired employees inducement options to purchase 65,000 shares of KalVista common stock. The options have an exercise price of $11.40 per share and vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
News
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. presented data at the 2024 HAEi Regional Conference Americas highlighting the negative impact of treatment delays on hereditary angioedema (HAE) patients. These delays lead to increased anxiety, quality of life issues, and suboptimal clinical outcomes, affecting both on-demand and prophylaxis patients. The company aims to address these challenges with sebetralstat, potentially improving compliance with treatment guidelines and enhancing disease control for HAE patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
Rhea-AI Summary
KalVista Pharmaceuticals receives Promising Innovative Medicine designation from UK MHRA for sebetralstat, an oral plasma kallikrein inhibitor for hereditary angioedema treatment, allowing early patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
none
-
News
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces positive results from the Phase 3 KONFIDENT clinical trial for sebetralstat, a potential first oral on-demand therapy for hereditary angioedema. The trial met all endpoints, demonstrating a favorable safety profile. The company closed a successful underwritten offering, appointing Benjamin L. Palleiko as the new CEO. Financially, the company reported no revenue for the quarter, with increased R&D and G&A expenses leading to a net loss of $29.0 million. Cash position decreased to $75.6 million as of January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
earnings
News
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announces the acceptance of multiple abstracts at the 2024 HAEi Regional Conference, showcasing research on hereditary angioedema treatment patterns and patient perceptions. The company is a Silver-level sponsor of the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences
-
News
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
Rhea-AI Summary
KalVista Pharmaceuticals appoints Benjamin L. Palleiko as CEO to lead the transition to a commercial entity with sebetralstat for HAE. NDA filing on track for H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
management
-
News
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (KALV) will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12th, 2024. The company focuses on oral protease inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
News
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. granted seven newly-hired employees inducement options to purchase 43,000 shares of KalVista common stock. The options have an exercise price of $14.14 per share and vest over a four-year period, subject to continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Stock KALV logo
KalVista Pharmaceuticals Inc

Nasdaq:KALV

KALV Rankings

#3064 Ranked by Market Cap
#326 Ranked by Stock Gains
N/A Ranked by Dividends

KALV Stock Data

501.62M
24.12M
1.14%
92.16%
13.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About KALV

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.